ライフサイエンスコーパス: fasting plasma glucose

1 e impact of type 2 diabetes risk variants on fasting plasma glucose.

2 e residue content correlated positively with fasting plasma glucose.

3 intervention-induced improvement in A1C and fasting plasma glucose.

4 es, who were matched for body-mass index and fasting plasma glucose.

5 The primary outcome was reduction in fasting plasma glucose.

6 P < 0.0001) but did not prevent the rise in fasting plasma glucose.

7 or elevated triglycerides, 18.95% for raised fasting plasma glucose.

8 aining current levels of body mass index and fasting plasma glucose.

9 -0.74, -0.01; P = 0.04) and had no effect on fasting plasma glucose.

10 ment induced glucosuria and markedly lowered fasting plasma glucose.

11 2 inhibition, despite an overall decrease in fasting plasma glucose.

12 ), once-weekly exenatide and albiglutide for fasting plasma glucose (-0.7 mmol/L [CI, -1.1 to -0.2 mm

13 Pioglitazone reduced fasting plasma glucose (10.0 +/- 0.7 to 7.5 +/- 0.6 mmol

14 Significant improvements in fasting plasma glucose (104.2 +/- 7.8 vs. 86.7 +/- 3.1 m

15 and pioglitazone also significantly improved fasting plasma glucose (-11+/-14 mg/dL; P=0.003), althou

16 categorized by the 1997 ADA IFG definition (fasting plasma glucose 110 to 125 mg/dl; 6.1 to 6.9 mmol

17 a significant decrease in concentrations of fasting plasma glucose (-17.1 +/- 14.8 compared with -0.

18 RSG improved fasting plasma glucose (185 +/- 8 to 139 +/- 5 mg/dl), m

19 ctors of type 2 diabetes mellitus, including fasting plasma glucose, 2-h post-load plasma glucose, an

20 Secondary outcomes included fasting insulin, fasting plasma glucose, 2-hour plasma glucose, and lipid

21 Fasting plasma glucose (5.4 +/- 0.1 vs. 5.1 +/- 0.1 mmol

22 ent treatment, near-normoglycemic remission (fasting plasma glucose 6.1 +/- 0.83 mmol/l and HbA1c 0.9

23 ascular disease mortality, and patients with fasting plasma glucose 70 to 79 mg/dL (3.89 to 4.43 mmol

24 (age 54 +/- 2 years, BMI 27.5 +/- 0.9 kg/m2, fasting plasma glucose 8.5 +/- 0.6 mmol/l) and 9 matched

25 risk compared with the risk in patients with fasting plasma glucose 80 to 109 mg/dL (4.44 to 6.05 mmo

26 on 13.5 years [7.3], HbA(1c) 8.3% [0.8], and fasting plasma glucose 9.2 mmol/L [3.1]); 618 (82%) and

27 ge 51 +/- 4 years, BMI 29.3 +/- 1.4 kg/m(2), fasting plasma glucose 9.3 +/- 0.7 mmol/l) during an int

28 Changes in fasting plasma glucose (-9.7 +/- 10.1 vs. +1.8 +/- 8.1 m

29 Compared with participants who had normal fasting plasma glucose, abnormal heart rate recovery was

30 d variants of rs2269023 were associated with fasting plasma glucose and 1-hour plasma glucose during

31 th the G/G-genotype had significantly higher fasting plasma glucose and 2-h insulin concentrations af

32 estriction and liraglutide treatment lowered fasting plasma glucose and A1C concentrations compared w

33 LB/cJ (BALB) exhibit distinct differences in fasting plasma glucose and atherosclerotic lesion size w

34 especified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin

35 Glycemic control as assessed by fasting plasma glucose and glycohemoglobin values was no

36 ar thickness (at 1 mm) and the levels of the fasting plasma glucose and glycosylated hemoglobin (HbA1

37 Fasting plasma glucose and glycosylated hemoglobin conce

38 lications yet test reliability is better for fasting plasma glucose and hemoglobin A1c than for the o

39 During pregnancy, fasting plasma glucose and hepatic glucose production we

40 uch as undernutrition, were replaced by high fasting plasma glucose and high body-mass index by 2013.

41 Whereas fasting plasma glucose and high-sensitivity C-reactive p

42 aglitazar for 3 months significantly lowered fasting plasma glucose and homeostasis model assessment

43 Fasting plasma glucose and insulin concentrations were m

44 tment for age, sex, percentage body fat, and fasting plasma glucose and insulin concentrations).

45 lin resistance (HOMA-IR) was calculated from fasting plasma glucose and insulin concentrations.

46 The mice also exhibit lower fasting plasma glucose and insulin levels and an increas

47 In addition, fasting plasma glucose and insulin levels increased and

48 remained severely insulin resistant based on fasting plasma glucose and insulin levels, and glucose a

49 Fasting plasma glucose and insulin were significantly hi

50 We measured serum lipids and lipoproteins, fasting plasma glucose and insulin, blood pressure (BP),

51 Fasting plasma glucose and lipid concentrations were als

52 litus, and who had available measurements of fasting plasma glucose and lipid concentrations within t

53 Fasting plasma glucose and lipid levels were measured be

54 r, there were no significant differences for fasting plasma glucose and lipid profiles within both gr

55 We documented a U-shaped relation between fasting plasma glucose and mortality.

56 l group comprised 64 individuals with normal fasting plasma glucose and normal glucose tolerance.

57 iated with cardiovascular disease, including fasting plasma glucose and possibly HDL-C.

58 s also suggested an inverse association with fasting plasma glucose and serum C-reactive protein but

59 eactive insulin was directly correlated with fasting plasma glucose and showed a significant inverse

60 l (TAD) will attenuate inflammation, improve fasting plasma glucose and triglyceride levels, body wei

61 Treatment with leptin normalized fasting plasma glucose and was accompanied by lowered Hb

62 and 46 patients with pre-DM showing impaired fasting plasma glucose and/or impaired oral glucose tole

63 (oral glucose tolerance test, basal insulin, fasting plasma glucose) and 1 postdonation RF, greater t

64 On stepwise multivariate analysis, age, sex, fasting plasma glucose, and BMI were the most important

65 sex, self-reported physical activity level, fasting plasma glucose, and BMI were used.

66 Atherosclerotic lesions in the aortic root, fasting plasma glucose, and body weight were measured.

67 20 mg, showed a greater reduction of HbA1c, fasting plasma glucose, and body weight.

68 llicle-stimulating hormone (FSH), prolactin, fasting plasma glucose, and insulin levels were measured

69 x group interaction for waist circumference, fasting plasma glucose, and lipid profiles within both g

70 ex, smoking status, hypertension prevalence, fasting plasma glucose, and serum cholesterol (CHOL).

71 rs6044695 and rs2284912 were associated with fasting plasma glucose, and variants of rs2269023 were a

72 nefits of the lower diagnostic threshold for fasting plasma glucose are not well defined.

73 resulted in a approximately 25% reduction in fasting plasma glucose, associated with a approximately

74 y endpoints were the change from baseline in fasting plasma glucose at week 2 and week 28, and 2 h po

75 iers have marginally lower concentrations of fasting plasma glucose (beta = -0.18 mmol l(-1), P = 1.1

76 tance to roadways was associated with higher fasting plasma glucose (beta = 2.17 mg/dL; 95% CI: -0.24

77 ndex, blood pressure, total cholesterol, and fasting plasma glucose, better health behaviors (diet, p

78 2 inhibitors group had significantly reduced fasting plasma glucose by 0.69 mmol/L [1.32; 0.07], glyc

79 Decreases in fasting plasma glucose (by approximately 1.7 mmol/l) and

80 cinnamon and turmeric as well as changes in fasting plasma glucose, cholesterol, and triacylglycerol

81 of serum leptin, fasting plasma insulin, and fasting plasma glucose compared to the control group.

82 d significantly after RDN, whereas mean (SD) fasting plasma glucose concentration (5.9 +/- 0.7 mmol/L

83 tes (mean age 38 years, body weight 81.7 kg, fasting plasma glucose concentration 83 mg/dL, and fasti

84 0.03 mmol x m(-2) x min(-1), P = 0.0009) and fasting plasma glucose concentration by 30% (to 10.8 +/-

85 Undiagnosed diabetes was defined as a fasting plasma glucose concentration of >/=126 mg/dL and

86 rly women in Denmark, we found that impaired fasting plasma glucose concentration was associated with

87 iometabolic risk factors (blood pressure and fasting plasma glucose concentration), along with binary

88 to <40 mg/dL, which is well below the normal fasting plasma glucose concentration.

89 se tolerance testing, and 22q12-13 linked to fasting plasma glucose concentration.

90 as accompanied by sustained normalization of fasting plasma glucose concentrations and HbA1c levels a

91 that, under normal physiological conditions, fasting plasma glucose concentrations are kept within a

92 Treatment increased fasting plasma glucose concentrations in all subjects (P

93 Fasting plasma glucose concentrations in each group were

94 Fasting plasma glucose concentrations increased after tr

95 Overall fasting plasma glucose concentrations, 2-hour postdextro

96 we obtained essentially identical effects on fasting plasma glucose concentrations.

97 In that group, fasting plasma glucose, current smoking, preexisting CHD

98 e significantly different in obese -/- mice: fasting plasma glucose decreased 13% (28 weeks), fed pla

99 he HFD induced insulin resistance, increased fasting plasma glucose, enhanced ceramide accumulation a

100 5-month intervals for up to 5 years or until fasting plasma glucose exceeded 140 mg/dl in Hispanic wo

101 rs890609/rs2269023 were also associated with fasting plasma glucose, fasting insulin and HOMA-IR.

102 Changes in fasting plasma glucose, fasting insulin, blood pressure,

103 etic resonance imaging and spectroscopy; (2) fasting plasma glucose, fasting plasma insulin (FPI), an

104 normal heart rate recovery added to impaired fasting plasma glucose for the prediction of death.

105 strategy, nor did titrating treatment using fasting plasma glucose (for areas without HbA1c testing)

106 ected 2 to 3 months after transplantation by fasting plasma glucose (fPG) >/= 7.0 mmol/L (>/= 126 mg/

107 osis, serum hemoglobin A1C (A1C) >/=6.5%, or fasting plasma glucose (FPG) >/=126 mg/dL, prediabetes a

108 30 years who were free of diabetes and had a fasting plasma glucose (FPG) <126 mg/dl at baseline.

109 IA severity correlated with fasting plasma glucose (FPG) (r = 0.662, P < 0.001) and

110 nately, tests such as hemoglobin A1c (HbA1c)/fasting plasma glucose (FPG) alone fail to diagnose or m

111 otype of rs964184 exhibited higher levels of fasting plasma glucose (FPG) and blood hemoglobin A1c (H

112 mated trends and their uncertainties in mean fasting plasma glucose (FPG) and diabetes prevalence for

113 ts all patients.We studied concentrations of fasting plasma glucose (FPG) and fasting insulin (FI) as

114 KLF6-IVS1-27 in healthy subjects and assayed fasting plasma glucose (FPG) and insulin sensitivities.

115 sociated with HS progression were changes in fasting plasma glucose (FPG) between biopsies (per 10 mg

116 sporter inhibition with empagliflozin on the fasting plasma glucose (FPG) concentration and beta-cell

117 been introduced that lowered the diagnostic fasting plasma glucose (FPG) concentration from 7.8 to 7

118 ich treatment most frequently attains target fasting plasma glucose (FPG) concentration of less than

119 We investigated the association of fasting plasma glucose (FPG) concentrations during pregn

120 c) is recommended for diabetes diagnosis but fasting plasma glucose (FPG) has been useful for identif

121 The sensitivity of fasting plasma glucose (FPG) in screening for new-onset

122 hemoglobin A1c level of 6.5% or greater or a fasting plasma glucose (FPG) level of 126 mg/dL or great

123 avenous glucose (AIR(gluc)) and the level of fasting plasma glucose (FPG) maintained in pancreas tran

124 ne HbA1c of 6.5% (48 mmol/mol) or greater or fasting plasma glucose (FPG) of 7.0 mmol/L or greater.

125 A fasting plasma glucose (FPG) test was used as the study

126 Fasting plasma glucose (FPG) was measured from capillary

127 Gestational fasting plasma glucose (FPG) was positively associated w

128 1Q (rs1044498) was associated with increased fasting plasma glucose (FPG), A1C, fasting insulin, and

129 ressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI)

130 baseline cut-point values of FINDRISC score, fasting plasma glucose (FPG), and HbA1c.

131 DE, which revealed association with HbA(1c), fasting plasma glucose (FPG), and mean fasting plasma gl

132 let function was assessed by measurements of fasting plasma glucose (FPG), intravenous glucose disapp

133 es in hemoglobin (Hb) A1c (primary outcome), fasting plasma glucose (FPG), serum N(euro)-(carboxymeth

134 culated for glycated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), total cholesterol (TC), tr

135 tors age, systolic blood pressure (SBP), and fasting plasma glucose (FPG), triglyceride, and high-den

136 olic blood pressures, body mass index (BMI), fasting plasma glucose (FPG), triglycerides (TG) and cho

137 pressure (SBP), total cholesterol (TC), and fasting plasma glucose (FPG).

138 s to assess progression from NGT to abnormal fasting plasma glucose (FPG; > or =6.1 mmol/l), abnormal

139 es Association (ADA) definition of diabetes (fasting plasma glucose [FPG] > or = 126 mg/dl on two occ

140 es with mild lifelong fasting hyperglycemia (fasting plasma glucose [FPG] 5.5-9.2 mmol/l, interquarti

141 DM patients (n = 10, age = 56 +/- 2.2 years, fasting plasma glucose [FPG] = 8.4 +/- 1.3 mmol/L, HbA(1

142 We used fasting plasma glucose, glucose tolerance tests, and sel

143 Waist circumference, body mass index, fasting plasma glucose, glycohemoglobin, low-density lip

144 pe 2 diabetes or abnormal glucose tolerance (fasting plasma glucose > or = 6.1 mmol/l or 2-h postchal

145 Diabetes was defined as a fasting plasma glucose > or = 7.0 mmol/L or treatment wi

146 s defined as casual glucose > or =200 mg/dL, fasting plasma glucose > or =126 mg/dL, or treatment.

147 diabetes at baseline (defined by treatment, fasting plasma glucose > or =7 or 2-h postchallenge gluc

148 ears for new cases of diabetes (treatment or fasting plasma glucose > or =7.0 mmol/l).

149 es adults) and >/= 88 cm (female adults); 2) fasting plasma glucose >/= 100 mg/dl; 3) blood pressure

150 The main outcome measures were diabetes (fasting plasma glucose >/= 126 mg/dL or taking medicatio

151 Participants who had a fasting plasma glucose >/=126 mg/dL and/or a 2-hour plas

152 >/=5.7 and <6.5% and (2) diabetes mellitus: fasting plasma glucose >/=126 mg/dL, 2-hour postload glu

153 Fasting plasma glucose had weaker associations with thes

154 pancreas were recruited for measurements of fasting plasma glucose, HbA1c, intravenous glucose toler

155 ular reactivity and systolic blood pressure, fasting plasma glucose, HDL cholesterol, fasting plasma

156 Because fasting plasma glucose, hemoglobin A1c, and the oral glu

157 roups revealed no significant differences in fasting plasma glucose, hemoglobin A1c, fasting insulin

158 metabolic factors (high SBP, high BMI, high fasting plasma glucose, high total cholesterol, and low

159 No significant differences were found for fasting plasma glucose, high-density lipoprotein cholest

160 he effect of both wines on glycemic control (fasting plasma glucose, homeostatic model assessment of

161 improves insulin sensitivity and normalizes fasting plasma glucose in diabetic UCD-T2DM rats, indepe

162 er 3 weeks on a high fat diet, the decreased fasting plasma glucose in transgenic mice compared with

163 were used to test for prediabetes, including fasting plasma glucose, insulin resistance (measured by

164 These animals showed lower fasting plasma glucose, insulin, and lactate levels and

165 Fasting plasma glucose, insulin, hemoglobinAIC, and gluc

166 Fasting plasma glucose is a multigenic trait related to

167 Fasting plasma glucose is strongly and independently ass

168 bnormal, the prognosis for patients with low fasting plasma glucose is unclear.

169 of age with newly diagnosed type 2 diabetes (fasting plasma glucose level > or = 7.8 mmol/L [140 mg/d

170 nce (World Health Organization criteria plus fasting plasma glucose level >or=5.3 mmol/L [>or=95 mg/d

171 ated to waist girth, triglyceride level, and fasting plasma glucose level (all p's < 0.001).

172 The OGCT and fasting plasma glucose level (at a threshold of 4.7 mmol

173 ed changes in body weight, insulin dose, and fasting plasma glucose level at 24 weeks and during the

174 lationship was found between CMT, HbA1c, and fasting plasma glucose level in either group (p=0.05).

175 outcomes associated with an increase in the fasting plasma glucose level of 1 SD (6.9 mg per decilit

176 ght patients aged 40 to 80 years with a mean fasting plasma glucose level of 12.0 mmol/L (216 mg/dL),

177 isk for diabetes (body mass index >24 kg/m2, fasting plasma glucose level of 5.2725 to 6.9375 mmol/L

178 was defined as a self-reported diagnosis or fasting plasma glucose level of 7.0 mmol/L (126 mg/dL) o

179 n level had poorer test characteristics than fasting plasma glucose level or the OGCT.

180 Data remained blinded if the fasting plasma glucose level was 105 mg per deciliter (5

181 s 7.5+/-1.2% in each group, whereas the mean fasting plasma glucose level was significantly lower in

182 Longer duration of diabetes and higher fasting plasma glucose level were associated with lower

183 2 years) with type 2 diabetes mellitus (mean fasting plasma glucose level, 11.2 mmol/L) who were bein

184 by a maximal exercise test on a treadmill), fasting plasma glucose level, and other clinical and per

185 nt for age, baseline cardiovascular disease, fasting plasma glucose level, high cholesterol level, ov

186 After further adjustment for fasting plasma glucose level, smoking, body mass index,

187 globin A1c level, and 171.3 (72.5) mg/dL for fasting plasma glucose level.

188 ner and exhibited a 37% (P<0.05) decrease in fasting plasma glucose level.

189 ars of quadrennial follow-up, was defined by fasting plasma glucose levels > or = 7.8 mmol/l at any t

190 ccurrence of one of four parameters: (i) two fasting plasma glucose levels >/= 126 mg/dL (>/= 7.0 mmo

191 kg/m2, RR = 1.64 [95% CI: 1.07-2.98]), high fasting plasma glucose levels (>/=126 mg/dL versus < 110

192 Fasting plasma glucose levels (Hedges g = 0.20; 95% CI,

193 ium in this population--were associated with fasting plasma glucose levels (P = 0.000017) and those 6

194 ting set, which is far superior to measuring fasting plasma glucose levels alone.

195 Participants with low fasting plasma glucose levels also had increased risk of

196 These changes were consistent with reduced fasting plasma glucose levels and altered expression of

197 women to investigate the association between fasting plasma glucose levels and cardiovascular disease

198 Elevated fasting plasma glucose levels associate with increased r

199 Fasting plasma glucose levels before the transplant are

200 the 8 mg/d metformin-rosiglitazone group and fasting plasma glucose levels by 2.2 mmol/L (39.8 mg/dL)

201 ant displayed significant worsening of their fasting plasma glucose levels during the 10-week observa

202 When used to target normal fasting plasma glucose levels for more than 6 years, ins

203 Participants with low fasting plasma glucose levels had a high risk of cardiov

204 We performed a genome scan for quantitative fasting plasma glucose levels in 320 families (1,514 sub

205 tal studies, administration of 2-AAA lowered fasting plasma glucose levels in mice fed both standard

206 Fasting plasma glucose levels in nondiabetic individuals

207 eproducibly associated with triglyceride and fasting plasma glucose levels in the general population.

208 Melatonin treatment significantly reduced fasting plasma glucose levels in the rats with DM.

209 Proportion of patients with fasting plasma glucose levels less than 126 mg/dL and Hb

210 ion of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular

211 ence of afternoon-examined participants with fasting plasma glucose levels of 7.0 mmol/L (126 mg/dL)

212 ldly diabetic phenotype, evidenced by higher fasting plasma glucose levels than wild-type mice.

213 tes and impaired fasting glucose levels, low fasting plasma glucose levels were also associated with

214 Body weight and fasting plasma glucose levels were determined weekly.

215 Fasting plasma glucose levels were greater in the NM gro

216 Mean (SD) fasting plasma glucose levels were higher in the morning

217 Fasting plasma glucose levels were reduced upon blockade

218 ndicated that high body mass index, elevated fasting plasma glucose levels, and nonalcoholic fatty li

219 rply higher for those in the top quartile of fasting plasma glucose levels, but increased linearly wi

220 everity of diabetes was evaluated by testing fasting plasma glucose levels, hemoglobin A1c levels, an

221 Glycosylated hemoglobin levels, fasting plasma glucose levels, insulin sensitivity, and

222 etes cases were identified by fasting or non-fasting plasma glucose levels, oral glucose tolerance te

223 Case-control studies reporting on fasting plasma glucose levels, plasma glucose levels aft

224 Standardized mean differences in fasting plasma glucose levels, plasma glucose levels aft

225 ability of dapagliflozin to improve fed and fasting plasma glucose levels.

226 Fasting plasma glucose, lipids, and 24-hour blood pressu

227 Blood samples were taken to assess fasting plasma glucose, low-density lipoprotein, high-de

228 Treatment was uptitrated to achieve target fasting plasma glucose <126 mg/dl; CHF medications were

229 and visceral adiposity in individuals with a fasting plasma glucose <6.4 mmol/l.

230 ory of cardiovascular disease, patients with fasting plasma glucose <70 mg/dL (<3.89 mmol/L) had a 3.

231 Although medical textbooks usually classify fasting plasma glucose <70 or 80 mg/dL (<3.89 or 4.44 mm

232 ears), drug-naive, type 2 diabetic subjects (fasting plasma glucose <or=10 mmol/l), we examined a rep

233 e (odds ratio 5.44 [2.63 to 11.27]), but not fasting plasma glucose (mean difference 0.03 mmol/L [-0.

234 can Diabetes Association guidelines based on fasting plasma glucose measurement and medication histor

235 ral-glucose-tolerance testing and semiannual fasting plasma glucose measurement.

236 and undiagnosed diabetes was determined with fasting plasma glucose measurements.

237 (1c), fasting plasma glucose (FPG), and mean fasting plasma glucose (mFPG) measured over 20 years.

238 Fasting plasma insulin, fasting plasma glucose, minimal model-derived insulin se

239 Liraglutide reduced mean fasting plasma glucose more than did exenatide (-1.61 mm

240 c intake and lower to normal metabolic rate, fasting plasma glucose, non-esterified fatty acids, chol

241 ated haemoglobin (HbA(1c)) of 8.5% (SD 1.1), fasting plasma glucose of 9.1 mmol/L (2.6), and weight o

242 e, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter

243 nge in the measurements of diabetic control (fasting plasma glucose or fructosamine) or by any change

244 There were no significant changes in fasting plasma glucose or lipids in conjunction with the

245 evealed no association with type 2 diabetes, fasting plasma glucose, or insulin sensitivity.

246 ch was fat loss, accompanied by decreases in fasting plasma glucose (P < 0.05) and triglycerides (P <

247 an overnight fast, women with GDM had higher fasting plasma glucose (P = 0.0001) and immunoreactive i

248 Fasting plasma glucose (P = 0.007) and homeostasis model

249 (P = 0.02), waist circumference (P < 0.001), fasting plasma glucose (P = 0.03), and triglycerides (P

250 nd postpartum weight reduction on changes in fasting plasma glucose (P-interaction = 0.03).

251 rs10401670 was also associated with fasting plasma glucose (Pe = 0.02, BMI adjusted) and mea

252 h body mass index, high blood pressure, high fasting plasma glucose, physical inactivity, and alcohol

253 had significantly lower glycated hemoglobin, fasting plasma glucose, plaque index, gingival index, pr

254 Body weight, fasting plasma glucose, plasma insulin, and intraperiton

255 imum inhibitory response correlated with the fasting plasma glucose (r = 0.75, P < 0.001) and insulin

256 n A1c values ranging from 5.7% to 6.4% or 2) fasting plasma glucose ranging from 100 to 125 mg/dL.

257 er response to gliclazide than to metformin (fasting plasma glucose reduction 4.7 vs 0.9 mmol/L, p=0.

258 Fasting plasma glucose remained an independent predictor

259 of only one of these tests is positive, then fasting plasma glucose should be tested to evaluate the

260 Fasting plasma glucose significantly decreased in the di

261 [-0.19 to -0.07], P<0.001, respectively; for fasting plasma glucose, standardized B=-0.09 [-0.15 to -

262 d the associations of body mass index (BMI), fasting plasma glucose, systolic blood pressure, and ser

263 , all once-weekly GLP-1RAs reduced HbA1c and fasting plasma glucose; taspoglutide, 20 mg, once-weekly

264 , and mice lacking hepatic Ppp1r3b had lower fasting plasma glucose than controls.

265 lipoprotein cholesterol, triglycerides, and fasting plasma glucose) that met criteria from the Natio

266 and FFA 17:0 were inversely associated with fasting plasma glucose, the area under the curve for glu

267 For a fasting plasma glucose threshold of 4.7 mmol/L (85 mg/dL

268 We used population distribution of fasting plasma glucose to measure exposure to higher-tha

269 , ambulatory blood pressure monitoring (BP), fasting plasma glucose, triglycerides (TG), cholesterol

270 ignificantly associated with blood pressure, fasting plasma glucose, triglycerides, and high-density

271 s, with measurements of BMI, blood pressure, fasting plasma glucose, triglycerides, HDL cholesterol c

272 The diagnostic fasting plasma glucose value for afternoon-examined part

273 ving hemoglobin A1c levels less than 6.5% or fasting plasma glucose values less than 126 mg/dL withou

274 Fasting plasma glucose was also inversely correlated wit

275 Neither 2hPG nor fasting plasma glucose was associated with death-censore

276 Fasting plasma glucose was associated with unadjusted bu

277 Fasting plasma glucose was measured every 3 months, and

278 n plasma lipid profiles, but a small rise in fasting plasma glucose was observed.

279 the genetic risk score on 5-year changes in fasting plasma glucose was stronger in individuals who i

280 In addition, higher glycohemoglobin A1c and fasting plasma glucose were associated with lower retina

281 se tissue, blood pressure, serum lipids, and fasting plasma glucose) were collected.

282 is study was to determine the association of fasting plasma glucose with abnormal heart rate recovery